Copy number variation and clinical response to chemotherapy and bevacizumab in the Czech metastatic colorectal cancer patients.

J StránskáK BartákováZ RožánkováL KotkováJ VrbkováR TrojanecP FlodrH JurtíkováB LíznerováJ Drábek

Published in: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti (2024)

In the pilot study, we found promising copy number variation biomarkers of bevacizumab response in FFPE samples of mCRC patients. The validation phase should be focused especially on the genes associated with angiogenesis (AGRN, MAPK8, ARHGAP22, LGALS13, LGALS4, ZFP36, and MYC), tumorigenesis (DVL1), and tumor proliferation (IFNL1, IFNL2, IFNL3, MAP3K10, and MAP4K1).

Keyphrases

copy number
mitochondrial dna
metastatic colorectal cancer
end stage renal disease
chronic kidney disease
ejection fraction
genome wide
prognostic factors
signaling pathway
dna methylation
patient reported